Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC
Public ClinicalTrials.gov record NCT02343952. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179
Study identification
- NCT ID
- NCT02343952
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Nasser Hanna, M.D.
- Other
- Enrollment
- 93 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 8, 2015
- Primary completion
- Aug 9, 2020
- Completion
- Dec 31, 2020
- Last update posted
- Sep 12, 2023
2015 – 2021
United States locations
- U.S. sites
- 15
- U.S. states
- 6
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | — |
| Fort Wayne Oncology & Hematology, Inc. | Fort Wayne | Indiana | 46845 | — |
| IU Health Goshen Hospital | Goshen | Indiana | 46527 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| IU Health Central Indiana Cancer Centers | Indianapolis | Indiana | 46219 | — |
| Community Regional Cancer Care | Indianapolis | Indiana | 49256 | — |
| IU Health Arnett Cancer Center | Lafayette | Indiana | 47904 | — |
| Horizon Oncology Research, Inc. | Lafayette | Indiana | 47905 | — |
| IU Health at Ball Memorial Hospital | Muncie | Indiana | 47303 | — |
| Oncology Hematology Associates of SW Indiana | Newburgh | Indiana | 47630 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46601 | — |
| University of Louisville, James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68114 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02343952, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 12, 2023 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02343952 live on ClinicalTrials.gov.